Vitiligo
Conditions
Keywords
CD63, CD9, Exosomal markers, Narrow-band ultraviolet B, NB-UVB, Immunohistochemistry, Vitiligo area severity index
Brief summary
This study evaluated the expression of the exosomal markers CD63 and CD9 in the skin of patients with vitiligo and assessed changes in their expression after narrow-band ultraviolet B (NB-UVB) therapy. Twenty patients with vitiligo were included and received NB-UVB therapy for 3 months. Clinical disease activity and severity were assessed using the Vitiligo Disease Activity (VIDA) score and the Vitiligo Area Severity Index (VASI) before and after treatment. Before treatment, skin biopsies were obtained from lesional and perilesional skin. After treatment, skin biopsies were obtained from repigmented areas. The tissue specimens were evaluated histopathologically and by immunohistochemical staining for CD63 and CD9. Twenty normal skin specimens obtained during plastic surgery were used as healthy controls for comparison.
Detailed description
Patients with clinically and dermoscopically diagnosed vitiligo were enrolled from the outpatient clinic of the Dermatology and Venereology Department, Tanta University Hospitals. Eligible patients had not received treatment for vitiligo during the 3 months before enrollment and provided written informed consent. At baseline, all patients underwent complete history taking, general and dermatological examination, assessment of disease activity using the Vitiligo Disease Activity (VIDA) score, and assessment of disease severity using the Vitiligo Area Severity Index (VASI). Before treatment, 4-mm punch biopsies were obtained from lesional and perilesional skin. The tissue specimens were formalin-fixed, paraffin-embedded, and processed for routine hematoxylin and eosin staining and immunohistochemical evaluation of the exosomal markers CD63 and CD9. Patients then received narrow-band ultraviolet B (NB-UVB) therapy for 3 months. After treatment, patients were clinically reassessed using VIDA and VASI. A 4-mm punch biopsy was obtained from repigmented skin to evaluate post-treatment changes in CD63 and CD9 expression. Twenty normal skin specimens obtained during plastic surgery were used as healthy controls. The expression of CD63 and CD9 was compared among lesional skin, perilesional skin, post-treatment repigmented skin, and normal control skin.
Interventions
RADIATIONNarrow-Band Ultraviolet B (NB-UVB) Therapy
Participants with vitiligo received narrow-band ultraviolet B (NB-UVB) phototherapy for 3 months as the study intervention.
Sponsors
Amany El-Agamy Ibrahim El-Samadony
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
A single group of patients with vitiligo received narrow-band ultraviolet B (NB-UVB) therapy for 3 months. Clinical and immunohistochemical assessments were performed before and after treatment. Normal skin specimens were used only as healthy controls for biomarker comparison and were not assigned to an intervention.
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients already diagnosed with vitiligo clinically and by dermoscopy. * Patients who did not receive any treatment for vitiligo for 3 months before joining the study. * Patients who accepted to be enrolled in the study and signed an informed consent.
Exclusion criteria
* Pregnant or lactating females. * Patients with allergy to local anesthesia. * Patients with a history of chronic debilitating diseases, autoimmune disorders, or other systemic diseases. * Patients with other dermatological diseases. * Patients with a history of bleeding disorders or receiving anticoagulant therapy. * Patients with a history of keloid or abnormal scar formation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in CD63 Immunohistochemical Expression Before and After NB-UVB Therapy. | Baseline and after 3 months of NB-UVB therapy. | CD63 expression was assessed by immunohistochemical staining in lesional skin at baseline and in repigmented skin after 3 months of narrow-band ultraviolet B (NB-UVB) therapy. CD63 expression was also compared with healthy control skin specimens. |
| Change in CD9 Immunohistochemical Expression Before and After NB-UVB Therapy. | Baseline and after 3 months of NB-UVB therapy. | CD9 expression was assessed by immunohistochemical staining in lesional skin at baseline and in repigmented skin after 3 months of narrow-band ultraviolet B (NB-UVB) therapy. CD9 expression was also compared with healthy control skin specimens. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Vitiligo Area Severity Index (VASI) After NB-UVB Therapy | Baseline and after 3 months of NB-UVB therapy | Vitiligo severity was assessed using the Vitiligo Area Severity Index (VASI), which ranges from 0 to 100. Higher scores indicate greater extent and severity of depigmentation and therefore a worse outcome. VASI was assessed at baseline and reassessed after 3 months of narrow-band ultraviolet B (NB-UVB) therapy to evaluate clinical response to treatment. |
| Change in Vitiligo Disease Activity (VIDA) Score After NB-UVB Therapy | Baseline and after 3 months of NB-UVB therapy | Vitiligo disease activity was assessed using the Vitiligo Disease Activity (VIDA) score, a 6-point scale ranging from -1 to +4. Higher scores indicate greater disease activity and therefore a worse outcome, while lower scores indicate more stable disease. VIDA was assessed at baseline and reassessed after 3 months of narrow-band ultraviolet B (NB-UVB) therapy. |
Countries
Egypt
Contacts
PRINCIPAL_INVESTIGATORAmany El-Samadony, MSc
Tanta University
Outcome results
None listed